

# Claudia Sommerer

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/38337/claudia-sommerer-publications-by-year.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

95  
papers

2,437  
citations

28  
h-index

46  
g-index

104  
ext. papers

3,025  
ext. citations

4.2  
avg, IF

4.47  
L-index

#	Paper	IF	Citations
95	Educational Attainment Is Associated With Kidney and Cardiovascular Outcomes in the German CKD (GCKD) Cohort.. <i>Kidney International Reports</i> , <b>2022</b> , 7, 1004-1015	4.1	2
94	Soluble Urokinase Receptor and Mortality in Kidney Transplant Recipients.. <i>Transplant International</i> , <b>2021</b> , 35, 10071	3	0
93	Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study. <i>BMJ Open</i> , <b>2021</b> , 11, e052138	3	0
92	Monitoring of gene expression in tacrolimus-treated de novo renal allograft recipients facilitates individualized immunosuppression: Results of the IMAGEN study. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 3851-3862	3.8	0
91	Bioimpedance analysis is not superior to clinical assessment in determining hydration status: A prospective randomized-controlled trial in a Western dialysis population. <i>Hemodialysis International</i> , <b>2021</b> , 25, 380	1.7	1
90	Effect of everolimus-based drug regimens on CMV-specific T-cell functionality after renal transplantation: 12-month ATHENA subcohort-study results. <i>European Journal of Immunology</i> , <b>2021</b> , 51, 943-955	6.1	3
89	Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study. <i>CKJ: Clinical Kidney Journal</i> , <b>2021</b> , 14, 277-283	4.5	1
88	Early prognostic performance of miR155-5p monitoring for the risk of rejection: Logistic regression with a population pharmacokinetic approach in adult kidney transplant patients. <i>PLoS ONE</i> , <b>2021</b> , 16, e0245880	3.7	3
87	Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	2
86	Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation. <i>Clinical Immunology</i> , <b>2021</b> , 229, 108792	9	0
85	Living Donor Kidney Transplantation in Patients With Donor-Specific HLA Antibodies After Desensitization With Immunoabsorption.. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 781491	4.9	0
84	Association of Serum Uromodulin with Death, Cardiovascular Events, and Kidney Failure in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2020</b> , 15, 616-624	6.9	5
83	Should kidney allografts from old donors be allocated only to old recipients?. <i>Transplant International</i> , <b>2020</b> , 33, 849-857	3	7
82	Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	6
81	Phase I trial of donor-derived modified immune cell infusion in kidney transplantation. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 2364-2376	15.9	18
80	After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. <i>Kidney International</i> , <b>2020</b> , 98, 1044-1052	9.9	35
79	Status of periodontal health in German patients suffering from chronic kidney disease-Data from the GCKD study. <i>Journal of Clinical Periodontology</i> , <b>2020</b> , 47, 19-29	7.7	4

78	Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR). <i>PLoS ONE</i> , <b>2019</b> , 14, e0222730	3.7	6
77	Effectiveness of different immunoadsorption columns for anti-A/B antibody depletion. <i>Atherosclerosis Supplements</i> , <b>2019</b> , 40, 68-72	1.7	2
76	Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography. <i>Scientific Reports</i> , <b>2019</b> , 9, 475	4.9	4
75	Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. <i>American Journal of Transplantation</i> , <b>2019</b> , 19, 3018-3034	8.7	51
74	An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients. <i>Kidney International</i> , <b>2019</b> , 96, 231-244	9.9	42
73	Outcomes and complications following ABO-incompatible kidney transplantation performed after desensitization by semi-selective immunoadsorption - a retrospective study. <i>Transplant International</i> , <b>2019</b> , 32, 1286-1296	3	9
72	Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients. <i>Transplantation Reviews</i> , <b>2019</b> , 33, 191-199	3.3	5
71	A need-adapted transition program after pediatric kidney transplantation. <i>Journal of Transition Medicine</i> , <b>2019</b> , 1,	1.6	3
70	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 261-307	3.2	163
69	Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study. <i>Transplantation</i> , <b>2019</b> , 103, 1953-1963	1.8	36
68	Clinical validation of a novel enzyme-linked immunosorbent spot assay-based in vitro diagnostic assay to monitor cytomegalovirus-specific cell-mediated immunity in kidney transplant recipients: a multicenter, longitudinal, prospective, observational study. <i>Transplant International</i> , <b>2018</b> , 31, 436-450	3	21
67	Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy. <i>American Journal of Transplantation</i> , <b>2018</b> , 18, 2965-2976	8.7	9
66	End-stage renal disease, dialysis, kidney transplantation and their impact on CD4 T-cell differentiation. <i>Immunology</i> , <b>2018</b> , 155, 211-224	7.8	19
65	Improved Pulse Wave Velocity and Renal Function in Individualized Calcineurin Inhibitor Treatment by Immunomonitoring: The Randomized Controlled Calcineurin Inhibitor-Sparing Trial. <i>Transplantation</i> , <b>2018</b> , 102, 510-520	1.8	5
64	Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2018</b> , 29, 317-325	12.7	39
63	Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2018</b> , 29, 1979-1991	12.7	123
62	Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study. <i>BMC Nephrology</i> , <b>2018</b> , 19, 154	2.7	2
61	Blood pressure control in chronic kidney disease: A cross-sectional analysis from the German Chronic Kidney Disease (GCKD) study. <i>PLoS ONE</i> , <b>2018</b> , 13, e0202604	3.7	12

60	Induction of Donor-Specific Immune Tolerance with Clinical MIC Cell Infusion in Phase I Study (TOL-1). <i>Blood</i> , <b>2018</b> , 132, 4539-4539	2.2	
59	Gender disparity in health-related quality of life and fatigue after living renal donation. <i>BMC Nephrology</i> , <b>2018</b> , 19, 377	2.7	4
58	1575. Clinical Validation of a Novel ELISpot-based in vitro Diagnostic Assay to Monitor CMV-Specific Cell-Mediated Immunity in SOT and HSCT Immunocompromised Patients. <i>Open Forum Infectious Diseases</i> , <b>2018</b> , 5, S491-S492	1	78
57	Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials. <i>BMC Nephrology</i> , <b>2018</b> , 19, 237	2.7	9
56	An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 799-807	4	3
55	Switch to an everolimus-facilitated cyclosporine A sparing immunosuppression improves glycemic control in selected kidney transplant recipients. <i>Clinical Transplantation</i> , <b>2017</b> , 31, e13024	3.8	11
54	Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial. <i>Nephrology Dialysis Transplantation</i> , <b>2017</b> , 32, 1060-1070	4.3	26
53	Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 2636-2650	3.8	36
52	The role of age-related T-cell differentiation in patients with renal replacement therapy. <i>Immunology and Cell Biology</i> , <b>2017</b> , 95, 895-905	5	4
51	Correlation between pharmacokinetics of tacrolimus and pharmacodynamics on NFAT-regulated gene expression in stable kidney transplant recipients?. <i>Clinical Nephrology</i> , <b>2017</b> , 87 (2017), 93-99	2.1	10
50	Secreted frizzled-related protein 4 predicts progression of autosomal dominant polycystic kidney disease. <i>Nephrology Dialysis Transplantation</i> , <b>2016</b> , 31, 284-9	4.3	7
49	Analytical Validation and Cross-Validation of an NFAT-Regulated Gene Expression Assay for Pharmacodynamic Monitoring of Therapy With Calcineurin Inhibitors. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 711-716	3.2	7
48	Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. <i>Trials</i> , <b>2016</b> , 17, 92	2.8	8
47	Nuclear Factor of Activated T Cells-Regulated Gene Expression as Predictive Biomarker of Personal Response to Calcineurin Inhibitors. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38 Suppl 1, S50-6	3.2	17
46	Everolimus immunosuppression in kidney transplantation: What is the optimal strategy?. <i>Transplantation Reviews</i> , <b>2016</b> , 30, 3-12	3.3	19
45	Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial. <i>Clinical Nephrology</i> , <b>2016</b> , 85, 215-25	2.1	7
44	Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease - cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort. <i>BMC Nephrology</i> , <b>2016</b> , 17, 59	2.7	12
43	Overhydration Is a Strong Predictor of Mortality in Peritoneal Dialysis Patients - Independently of Cardiac Failure. <i>PLoS ONE</i> , <b>2016</b> , 11, e0158741	3.7	25

42	Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38 Suppl 1, S1-20	3.2	57
41	Analytical Aspects of the Implementation of Biomarkers in Clinical Transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38 Suppl 1, S80-92	3.2	5
40	Target Enzyme Activity and Phosphorylation of Pathway Molecules As Specific Biomarkers in Transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38 Suppl 1, S43-9	3.2	5
39	Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. <i>Clinical Nephrology</i> , <b>2015</b> , 83, 11-21	2.1	30
38	High interpatient variability in response to mycophenolic acid maintenance therapy in patients with ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30 Suppl 1, i138-45	4.3	10
37	Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial. <i>Journal of Nephrology</i> , <b>2015</b> , 28, 115-23	4.8	15
36	Evolution of allograft fibrosis and function in kidney transplant recipients: a retrospective analysis of stable patients under CNI and mTORi. <i>Transplant International</i> , <b>2015</b> , 28, 553-64	3	8
35	Psychosocial and physical outcome following kidney donation-a retrospective analysis. <i>Transplant International</i> , <b>2015</b> , 28, 416-28	3	14
34	Monitoring of calcineurin inhibitors by NFAT-regulated gene expression in de novo renal allograft recipients on cyclosporine A. <i>Clinical Nephrology</i> , <b>2015</b> , 84, 165-72	2.1	8
33	The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial. <i>Trials</i> , <b>2014</b> , 15, 489	2.8	13
32	Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study. <i>Annals of Transplantation</i> , <b>2014</b> , 19, 32-40	1.4	21
31	Current pharmacotherapeutical options for the prevention of kidney transplant rejection. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 1029-41	4	0
30	Assessment of renal allograft fibrosis by transient elastography. <i>Transplant International</i> , <b>2013</b> , 26, 545-51	3	45
29	Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. <i>Transplant International</i> , <b>2012</b> , 25, 506-17	3	47
28	Calcineurin inhibitors and NFAT-regulated gene expression. <i>Clinica Chimica Acta</i> , <b>2012</b> , 413, 1379-86	6.2	37
27	Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. <i>Lancet, The</i> , <b>2011</b> , 377, 837-47	4.0	294
26	Safety and efficacy of intensified versus standard dosing regimens of enteric-coated mycophenolate sodium in de novo renal transplant patients. <i>Transplantation</i> , <b>2011</b> , 91, 779-85	1.8	24
25	Pharmacodynamic disparities in tacrolimus-treated patients developing cytomegalus virus viremia. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 373-9	3.2	22

24	Cyclosporine-induced gingival overgrowth correlates with NFAT-regulated gene expression: a pilot study. <i>Journal of Clinical Periodontology</i> , <b>2011</b> , 38, 984-91	7.7	8
23	Immunomonitoring of nuclear factor of activated T cells-regulated gene expression: the first clinical trial in liver allograft recipients. <i>Liver Transplantation</i> , <b>2011</b> , 17, 466-73	4.5	24
22	Pharmacodynamic monitoring of cyclosporin A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 694-8	3.2	28
21	Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. <i>British Journal of Clinical Pharmacology</i> , <b>2010</b> , 69, 346-57	3.8	49
20	Pharmacodynamic monitoring of cyclosporine A by NFAT-regulated gene expression and the relationship with infectious complications in pediatric renal transplant recipients. <i>Pediatric Transplantation</i> , <b>2010</b> , 14, 844-51	1.8	18
19	Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. <i>Rheumatology</i> , <b>2010</b> , 49, 2061-7	3.9	28
18	Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2010</b> , 5, 503-11	6.9	36
17	Approaches towards individualized immune intervention. <i>Digestive Diseases</i> , <b>2010</b> , 28, 45-50	3.2	10
16	Biomarkers as a tool for management of immunosuppression in transplant patients. <i>Therapeutic Drug Monitoring</i> , <b>2010</b> , 32, 560-72	3.2	46
15	Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. <i>Transplantation</i> , <b>2010</b> , 89, 1417-23	1.8	37
14	New concepts to individualize calcineurin inhibitor therapy in renal allograft recipients. <i>Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia</i> , <b>2010</b> , 21, 1030-7	0.6	4
13	Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in 5/6 nephrectomized rats. <i>American Journal of Physiology - Renal Physiology</i> , <b>2009</b> , 297, F769-80	4.3	25
12	AEB071--a promising immunosuppressive agent. <i>Clinical Transplantation</i> , <b>2009</b> , 23 Suppl 21, 15-8	3.8	10
11	Monitoring immunosuppression with measures of NFAT decreases cancer incidence. <i>Clinical Immunology</i> , <b>2009</b> , 132, 305-11	9	17
10	Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients. <i>Clinical Transplantation</i> , <b>2008</b> , 22, 549-54	3.8	33
9	Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression. <i>Transplantation</i> , <b>2008</b> , 85, 15-21	1.8	51
8	Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. <i>Journal of Hypertension</i> , <b>2008</b> , 26, 2213-9	1.9	38
7	Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. <i>Transplantation</i> , <b>2008</b> , 86, 1043-51	1.8	209

6	Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients. <i>Transplant International</i> , <b>2007</b> , 20, 1036-43	3	30
5	Cardiac biomarkers in haemodialysis patients: the prognostic value of amino-terminal pro-B-type natriuretic peptide and cardiac troponin T. <i>Nephron Clinical Practice</i> , <b>2007</b> , 107, c77-81		16
4	Rapid deterioration of renal function in a long-term allograft recipient with recurrent IgA nephritis--is it the only cause?. <i>Nephrology Dialysis Transplantation</i> , <b>2007</b> , 22, 3079-81	4-3	
3	Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. <i>Transplantation</i> , <b>2006</b> , 82, 1280-5	1.8	68
2	The long-term consequences of living-related or unrelated kidney donation. <i>Nephrology Dialysis Transplantation</i> , <b>2004</b> , 19 Suppl 4, iv45-7	4-3	19
1	Cyclosporin A toxicity of the renal allograft--a late complication and potentially reversible. <i>Nephron</i> , <b>2002</b> , 92, 339-45	3-3	24